Sunanda Singh, MD, PhD

Company: Singh Biotechnology

Job title: CEO

Seminars:

Targeting KRAS Mutants with Cell-Penetrating Nano-Antibody (SBT-100) for Mutation Agnostic RAS Therapy 11:45 am

Inhibiting KRAS and its mutants using cell and BBB penetrating nano-antibody SBT-100 provides a targeted and effective treatment option Minimizing toxicity to host enables safer targeting of RAS due to non-covalent binding of KRAS by SBT-100 Examining how to take a multi-target approach by inhibiting KRAS, KRAS(G12D), and KRAS(G13D) with just one nano-antibody for a…Read more

day: Day Two Track A AM